Further reading
Boome DR, Girguis M, Baron P, Cottrel A, Kjellin I, Kirk G (2007) Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Roentgenol 188:586–592
Center for Disease Control and Prevention (CDC) (2007) Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents-St. Louis, Missouri, 2002–2006. MMWR Morb Mortal Wkly Rep 56:137–41
Collidge TA, Thompson PC, Mark PB et al (2007) Gadolinium-enhanced magnetic resonance imaging and nephrogenic systemic fibrosis—a retrospective case-control study. Radiology (in press)
Deo A, Fogel M, Cowper SE (2007) Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2:264–267
EMEA decision of 26.06.07. Available through http://www.esur.org. Assessed 10.08.07
Grobner T (2006) Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104–1108
High W, Ayers RA, Chandler J, Zito G, Cowper SE (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:27–30
Idée J-M, Port M, Raynal I, Schaefer, Le Greneur S, Corot C (2006) Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20:563–576
Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE (2007) Nephrogenic systemic fibrosis. A review of 6 cases romporally related to gadodiamide injection (Omniscan). Invest Radiol 42:139–145
Maloo M, Abt P, Kashyap R et al (2006) Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transpl 6:2212–2217
Marckman P, Skov L, Rossen K et al (2006) Nephrogenic systemic fibrosis: suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359–2362
Morcos, SK (2007) Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast molecule an important factor in the pathogenesis of this condition? Brit J Radiol 80:73–76
Sadowski E, Bennett LK, Chan MR et al (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 43:148–157
Thomsen HS (2006) Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol 16:2619–2621
Thomsen HS, Almén T, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (2002) Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol 12:2600–2605
Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR) (2005) In which patients should serum-creatinine be measured before contrast medium administration? Eur Radiol 15:749–754
Author information
Authors and Affiliations
Corresponding author
Additional information
The content of this document presents the consensual opinion of only the Academic members of the ESUR Contrast Media Safety Committee.
Rights and permissions
About this article
Cite this article
Thomsen, H.S. ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol 17, 2692–2696 (2007). https://doi.org/10.1007/s00330-007-0744-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-007-0744-5